OKLAHOMA
Health Care Authority

State of Oklahoma
SoonerCare
Danyelza® (Naxitamab-gqgk) Prior Authorization Form

Member Name:_____ ***Date of Birth:***_____ ***Member ID#:***_____

Drug Information

Physician billing **(HCPCS code:**_____**)** ***Start Date*** **(or date of next dose):**_____

Dose:_____ ***Regimen:***_____

Billing Provider Information

Provider NPI:_____ ***Provider Name:***_____

Provider Phone:_____ ***Provider Fax:***_____

Prescriber Information

Prescriber NPI:_____ ***Prescriber Name:***_____

Prescriber Phone:_____ ***Prescriber Fax:***_____ ***Specialty:***_____

Criteria

For Initial Authorization:

❑ **Neuroblastoma**

1. Is diagnosis relapsed or refractory high-risk neuroblastoma? Yes____ No____
2. Is disease in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy (i.e., no progressive disease following most recent therapy)? Yes____ No____
3. Will naxitamab-gqgk be used in combination with a granulocyte-macrophage colony-stimulating factor (GM-CSF) according to package labeling (GM-CSF dosed at 250mcg/m^2/day daily starting 5 days prior to Danyelza® therapy and 500mcg/m^2/day daily on days 1 to 5 of Danyelza® therapy)? Yes____ No____
4. Does prescriber agree to provide the member appropriate premedication for pain management and neuropathic pain (e.g., oral opioids, gabapentin)? Yes____ No____
5. Does prescriber agree to provide the member appropriate premedication for infusion-related reactions and nausea/vomiting including an intravenous (IV) corticosteroid, a histamine 1 (H_1) antagonist, an H_2 antagonist, acetaminophen, and an antiemetic? Yes____ No____

❑ **If answer is none of the above, please indicate diagnosis:**_____

Additional Information:_____

For Continued Authorization:

1. Date of last dose:_____
2. Does member have any evidence of progressive disease while on naxitamab-gqgk? Yes____ No____
3. Has the member experienced adverse drug reactions related to naxitamab-gqgk? Yes___ No___

*If yes, please specify adverse reactions:*_____

Prescriber Signature: _____ **Date:**_____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*